ArticleChinese medical journal2026
Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) is an emerging subtype with specific clinicopathological features and therapeutic strategies. However, limited studies are available on the molecular characteristics and prognosis of triple-negative breast cancer (TNBC).
methodsThis study was conducted using the clinicopathological and genomic data of 1006 TNBC patients, which were extracted from The Cancer Genome Atlas (TCGA), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), and Sir Run Run Shaw Hospital of Zhejiang University (SRRSH) cohorts. The clinicopathological features, survival outcomes, molecular characteristics, and immune profiles of TNBCs based on HER2 status were evaluated.
resultsPatients were stratified into HER2-low ( N = 676) and HER2-zero ( N = 330) groups according to their HER2 status. We found HER2-low TNBCs had a lower histological grade and Ki67 index compared to the HER2-zero subgroup in the SRRSH cohort. However, no significant association has been found between the HER2 status and the disease-free survival (DFS), recurrence-free survival (RFS), or overall survival (OS) in TNBCs. Genomic mutation analysis showed that the HER2-low TNBCs exhibited higher mutated frequencies of PIK3CA, MUC17 , and PTEN , while FAT3, RYR2 , and CSMD3 were more frequently mutated in the HER2-zero subgroup. Furthermore, the combined mutation of PIK3CA and MUC17 , which had a higher frequency in the HER2-low subgroup, was associated with poorer survival in TNBCs. Immune profile analysis revealed a higher percentage of plasma cells in patients with low HER2 expression.
conclusionTaken together, our study reflected the impact of the HER2 status on the clinicopathological and molecular features of TNBCs, which might offer additional introspection and improvement for translational studies and therapeutic decisions for TNBCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.